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Abstract:  We review our work over the past 14 years that began when we were first 
confronted with bimodal relapse patterns in two breast cancer databases from different 
countries.  These  data  were  unexplainable  with  the  accepted  continuous  tumor  growth 
paradigm.  To  explain  these  data,  we  proposed  that  metastatic  breast  cancer  growth 
commonly includes periods of temporary dormancy at both the single cell phase and the 
avascular micrometastasis phase. We also suggested that surgery to remove the primary 
tumor often terminates dormancy resulting in accelerated relapses. These iatrogenic events 
are apparently very common in that over half of all metastatic relapses progress in that 
manner. Assuming this is true, there should be ample and clear evidence in clinical data. 
We  review  here  the  breast  cancer  paradigm  from  a  variety  of  historical,  clinical,  and 
scientific  perspectives  and  consider  how  dormancy  and  surgery-driven  escape  from 
dormancy would be observed and what this would mean. Dormancy can be identified in 
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these diverse data but most conspicuous is the sudden synchronized escape from dormancy 
following primary surgery. On the basis of our findings, we suggest a new paradigm for 
early stage breast cancer. We also suggest a new treatment that is meant to stabilize and 
preserve dormancy rather than attempt to kill all cancer cells as is the present strategy. 
Keywords:  breast  cancer;  dormancy;  surgery  induced  growth;  mammography; 
chemotherapy; primary antiangiogenic therapy 
 
1. Introduction 
We are taught by the scientific method that there are experiments and there are theories. Theories 
are proposed to explain data and experiments are performed to test theories. When there is satisfactory 
agreement between theory and experiment we begin to accept that the theory is likely valid and may 
move on to study other systems. But what happens when there is disagreement between theory and 
experiment?  It does not matter how long the theory has been around or who has endorsed it, if theory 
and experiment disagree, we are obligated by the scientific method to reexamine the theory. 
In this paper we review our work over the past 14 years that challenges the validity of a main 
underlying theoretical paradigm that in some important ways guides intervention of breast cancer.  
This paradigm is based on the dogma that metastatic breast tumor growth is continuous. If that is not 
true, as a necessary corollary to discontinuous growth, dormant phases may be only quasi-stable and 
may be interrupted by an intervention or other external change. We will show that while dormancy is 
most observable in laboratory environments as delayed tumor growth after cancer cell implant, the 
sudden escape from dormancy is the most conspicuous effect in clinical breast cancer especially when 
synchronized. (Note: There are other options, but the traditional way relapse data are presented in 
clinical oncology is to treat many patients similarly and then graph the fraction who have not relapsed 
with metastatic disease measuring each from the time they had surgical removal of the primary tumor.  
This has the effect in data presentation of artificially synchronizing all patients to surgery even though 
each was treated at different calendar dates.)  Millions of healthy women have been screened for 
cancer  and  cancer  patients  have  been  treated  by  interventions  based  on  the  continuous  growth 
assumption. We are of the opinion that interventions should best be guided by better knowledge of 
how tumors grow. 
The burden is on us to first show that evidence in support of continuous growth is not strong. Then 
we have to show that the growth model that we propose provides better agreement with clinical data. 
As will be seen, growth description of breast cancer plays an important role in unexpected and far 
ranging areas of clinical breast cancer. In this paper we will cover these aspects of clinical data and 
explain in some detail why the continuous model fails and why the new model we have proposed is 
probably closer to a true description based on its ability to provide explanations to a wide variety of 
effects that were previously thought to be unconnected. 
Just  to  cast  early  doubt  on  continuous  growth  and  to  show  the  importance  of  quantitatively 
understanding tumor growth in clinical breast cancer we will discuss a subject of high current interest. 
Mammographic screening for early detection of breast cancer is a widely accepted and long used tool Cancers 2010, 2                                      
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in attempts to reduce the mortality and morbidity from the disease.  But lately there have been some 
very public disturbing developments. In the UK in March 2009, a group of scientists, physicians and 
advocates in a published letter to Times of London criticized the National Health Service for not 
providing honest information on harms from mammography. They cite the report from the Cochrane 
organization that 2000 women need to be screened for 10 years to save one additional life from breast 
cancer but in the process, 10 women will be over-diagnosed and be treated for a condition that does not 
need to be treated. The National Health Service has agreed to review the information on possible 
harms provided to women when invited to participate in mammography screening for early detection 
of breast cancer. This was a significant news event in the UK. A very short time later, in the United 
States, the U.S. Preventive Services Task Force reversed their previous recommendation and now does 
not suggest routine mammography for women age 40–49. This was a major news event in the US in 
November 2009 and caused much consternation. How tumors grow plays a key role in explaining 
these highly controversial events. 
Breast cancers typically start as cells in the milk ducts of the breast that somehow or other become 
transformed into a state capable of malignant growth. They can grow in the duct and, while remaining 
there, are called ductal carcinoma in situ or DCIS. Some may ultimately invade the breast tissue and 
are then capable of producing a tumor that can lead to dangerous breast cancer. However, other cases 
of DCIS may never invade the tissue in the remaining life of the patient.  
A  problem  stems  from  the  fact  that  DCIS  cannot  presently  be  classified  into  those  that  are 
dangerous and need to be treated or those that are destined never to invade and can be safely watched 
or even ignored.  This might never be possible by studying the pathological focus itself as the secret 
might lie with the host stroma and local cytokine production. (See New York Times feature December 
29,  2009)  Mammography  is  quite  good  at  finding  DCIS.  But  then  what  does  one  do  when  that 
happens? Surgical removal is 100% curative but it may not be necessary. This is not a small problem. 
Approximately 20% of all abnormal findings in mammography are DCIS and while the number is in 
dispute,  20%  to  50%  of  DCIS  never  would  invade  in  the  subject‘s  lifetime.  So  it  turns  out  that 
mammography  saves  lives  but  there  are  possible  serious  harms.  Treatment  involves  surgery  and 
perhaps more extensive therapy if the physician or the patient is sufficiently concerned. The DCIS 
conundrum is rarely disclosed in public since it is thought that if women were told this they might not 
opt  for  mammography.  Getting  women  screened  with  mammography  is  a  major  goal  of  some 
organizations so this information is withheld as its release will be contrary to achieving their goal. This is 
highly patronizing to women. It has been described as ―Mommy knows best‖ as if talking to a child [1]. 
As other evidence, according to a Danish report, 39% of forensic autopsies of women age 40–49 
show clinically occult breast cancer, a number much larger than the lifetime risk of breast cancer of 
13% in US and 8% in Denmark [2,3]. Based on this information alone, it could legitimately be argued 
that mammography should not be routinely recommended for women age 40–49.  
These examples, strongly suggesting that breast tumor growth is not always continuous, well serve 
to demonstrate the importance of quantitatively understanding tumor growth and what trouble can be 
caused when medical interventions are guided by dogma rather than by solid data. Health science 
policy has gotten ahead of health science. It behooves us to better understand how tumors grow. 
In the following sections we present arguments as to why we consider the continuous growth model 
inaccurate and why we consider the new model to better describe clinical breast cancer. In addition to Cancers 2010, 2                                      
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the  introduction  and  conclusion,  there  are  three  separate  sections  to  this  document  that  may  be 
considered as adjoining essays. Each was the responsibility of one of the authors. The authors have 
various medical and scientific backgrounds (and writing styles) that may be apparent. Redundancy of 
some information was impossible to prevent especially since there are a few early key developments 
that formed the basis of our ideas and led us along various paths that are presented here. 
The phrase ―an inconvenient truth‖ in our title is borrowed from both the poignant message on 
global  warming  from  Al  Gore  and  a  recent  paper  by  Buxton  et  al.  [4]  proposing  a  biological 
mechanism that might explain our findings. 
 
2. Models, Cancer Models and the Natural History of Breast Cancer 
 
2.1. The Natural History of Breast Cancer 
 
The  expression  ―Natural  History‖  has  two  meanings.  Historically  it  has  come  to  mean  the 
systematic study of all natural objects, hence the famous collection of dinosaur skeletons, trilobite 
fossils and Darwin‘s specimens from the Galapagos Islands in the Natural History Museum, South 
Kensington, London. Another meaning to this expression used as a medical term, is the behavior of a 
disease in the absence of treatment or in other words left to nature. 
In the modern world we accept the concept that many minor ailments are self limiting and jokingly 
reassure our friends that their bad cold will get better in a week, but with whiskey, a warm bed and 
tender loving care it will only take seven days! 
With more serious conditions that are life threatening or could lead to chronic dysfunction we treat 
in order to influence this natural history in a favorable direction and rely on the history books to tell us 
what would have happened without treatment but with careful observation alone. Unfortunately in the 
days  before  active  treatment  of  serious  disease,  careful  and  systematic  observation  were  also 
exceptional. And this applies in particular to carcinoma of the breast. 
Another relevant issue here is that we don‘t always see in a dispassionate way the objective reality 
of that which we observe but more likely a distortion, refracted through the prism of our personal 
prejudices.  Observations  that  reinforce  our  prejudices  are  embraced  and  those  that  challenge  our 
beliefs are ignored or rationalized away. 
In this section we wish to concentrate on the natural history of breast cancer and the evolution of 
conceptual models to explain its behavior. We propose that all this is fundamental to improving the lot 
of our suffering patients for the simple reason that our treatments are the therapeutic consequence of 
our  belief  in  the  underlying  mechanisms  of  disease.  In  other  words  belief  systems  and  treatment 
modalities are two sides of the same coin. 
 
2.2. The Nature of Models and Models of Nature 
 
A model car we understand but a model of nature, what can that mean? Let us explain. Models are 
not just mechanical miniatures of the real thing; they can be anything else which helps to capture the 
very essence of the subject of our scrutiny. They can be metaphysical, mechanistic, biological or 
mathematical. Many sports car enthusiasts keep perfect replicas scaled down to 1:1000 on their desks Cancers 2010, 2                                      
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in preference to photographs of their wives and children. This is a mechanical model. Their wives view 
the contraption as the work of the devil, that if you like is a metaphysical model and finally the 
mechanical engineer can reproduce the energy of the internal combustion unit and the torque of the 
transmission system as mathematical formulae. That is a mathematical model. 
 
2.3. An Organic Example is the Rose Bush 
 
Easier to handle is the mechanistic model in a children‘s primary school botany book. Here the rose 
is built up of petals, sepals, stamens, filament, anther and carpel all connected to a stalk with leaves, 
thorns and roots. It loses its poetry when broken down this way. Even more so when the reductionists 
do their worst and the rose is described as a molecular model. Curiously enough, much of the beauty 
and mystery of the rose reappears in its mathematical model. 
The new mathematics of Fibonacci numbers, fractals and Lindenmayer systems allow us to generate 
beautiful floribunda on our computer screens thus linking the mathematical model of the rose to the 
greater symmetries and complex patterns in nature [5]. 
 
2.4. The Natural History of an Automobile and a Rose 
 
Left  to  nature  an  automobile  will  rust  and  its  engine  will  seize  up.  As  our  knowledge  of  the 
automobile and of the mechanism of rusting developed in tandem we have a ready explanation for this 
process, which is well understood. 
The chemical reaction between iron and oxygen in the presence of moisture leads to corrosion and 
the production of iron oxide. We can influence this natural history by keeping the car dry, well oiled 
and locked away. With luck the automobile will now last us up to 20 years - its maximum expectation 
of life. 
The rose has a different and much more complex natural history. Left to nature it will enjoy an 
annual cycle of renewal, flowering every summer, resting every winter and springing into bud each 
spring. In addition, left to nature, it grows into angry knots; it develops suckers with seven leaves 
instead of five on each stem, which grow to prodigious lengths. Then holes appear in the leaves, brown 
patches of rust add to their disfigurement and green flies infest and destroy the buds. In the bad old 
days you could accuse your neighbor of witchcraft for blighting your bushes (a metaphysical model of 
disease) but in this modern era we know that the ―rust‖ is a fungus (Puccinia basdiomycetes) and the 
holes are thanks to the caterpillars. We can influence this natural history with the aid of scientific 
horticulture, by pruning in February, putting phosphates down in March and spraying with inorganic 
chemicals all summer.  
 
2.5. The History of Ideas Concerning the Nature of Breast Cancer 
 
After that long preamble, the relevance of which will become clear, we wish to return to the natural 
history of breast cancer. If left untreated what would happen and of equal importance, why?  Cancers 2010, 2                                      
 
 
310 
In addition to its sensual beauty, the breast was revered by the ancients as closely associated with 
menstrual bleeding, pregnancy and child nourishing or nothing short of propagation of the species [4]. 
Aristotle stated that ―menses goes to the breasts and becomes milk―. 
The very earliest record of breast tumors is from the Egyptian Pyramid Age (3000–2500 BC). It is 
believed that Imhotep, the earliest known physician wrote: ―If you examine a man (we are also seeing 
an early case of gender bias) having bulging tumors on his breast, and you find that they have spread 
over his breast; and you place your hand upon his breast tumors and you find them to be cool, there 
being no fever at all therein when your hand feels them; they have no granulations; contain no fluid; 
give rise to no liquid discharge, yet they feel protuberant to your touch, you should say concerning 
him: this is a case of bulging tumors I have to contend with.‖ 
This  elementary  differential  diagnosis  rules  out  inflammatory  diseases  or  abscesses.  As  for 
treatment: ―There is no treatment.‖ 
Today all physicians take the Hippocratic Oath. While Hippocrates (400 BC) made little mention of 
breast cancer, he noted that it was better to give no treatment for deep seated tumors because treatment 
accelerated the death process, but if one omitted treatment, life might be prolonged. This is of course 
relative to the 18 year average life span in those times. There were three precepts established by 
Hippocrates:  those  diseases  that  are  curable  by  medicine  are  best,  those  that  are  not  curable  by 
medicine may be curable by the knife, and those that are not curable by the knife may be curable by 
fire. Those incurable by fire are incurable. It is doubtful that surgery to cure a breast cancer was ever 
recommended by Hippocrates. 
While not a physician, Aulus Cornelius Celsus (30 BC to 38 AD) wrote extensively about medicine 
and science. Celsus was opposed to surgery and cautery for advanced breast cancer. If in doubt, he 
recommended local application of caustics. If there was some improvement, then one could conclude 
that it was not cancer and then consider surgery or cautery. If there was no improvement, one should 
conclude that it was cancer and withhold treatment so as not to hasten demise of the patient.  
Moving forward 200 years, we encounter Galen of Pergamum (131 to 203 AD) who first associated 
cancer with the crab and was probably responsible for the first routinely successful surgical treatment 
of cancer. ―Just as a crab has legs on both sides of his body, so in this disease the veins extending out 
from the unnatural growth take the shape of crab‘s legs.‖ 
He further states: ―We have often cured this disease in the early stages, but after it has grown to a 
noticeable size no one has cured it with surgery. In all surgery we attempt to excise a pathologic tumor 
in a circle in the region where it borders on the healing tissue.‖ Galen was describing how to provide a 
clear margin. 
Ligatures that are used today to tie off blood vessels were not used in Galen‘s time since they were 
thought to spread the cancer. Galen contended that cancer was caused by ―humors‖, a theory that 
dominated medicine for 1000 years. Cancer was due to an excess of black bile or humor.  
Paulus Aegineta (7th century) Greek surgeon agreed with Galen that humors caused cancer. He 
wrote: ―... if overheated it is attended with ulceration, and owing to the thickness of the tumor, cancer 
of the breast is an incurable disease, for it can neither be repelled not discussed; not yielding to purging 
of the whole body, resisting the milder applications and being exasperated by the stronger ones. The 
only chance for a radical cure consisted in taking a complete excision of the part.‖ Cancers 2010, 2                                      
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Rhazes (841-926), an Arabian physician, warned those who incised a breast cancer would only 
produce an ulceration and that only if the breast could be completely removed and the parts burned 
should an excision be done. He approved of cooling the breast if ulcerations have occurred. 
Versalius (1514-1564) was one of the first to challenge Galen‗s humor theory. He published an 
anatomy book in 1543 that marks the beginning of modern anatomy. His study of the breast anatomy 
paved the way for new surgical techniques to improve breast cancer surgery. 
An important contributor to the development of the treatment of breast cancer was Ambrose Pare 
(1510-1590), a French surgeon who stated: "If the cancer was small, non-ulcerated, and situated in a 
region where it could be easily removed, the tumor should be excised, but one should go well beyond 
its boundaries." Large and ulcerated lesions were treated with sweet milk, vinegar, and ointments. Pare 
called attention to the fact that the primary breast cancer and the axillary extension of the breast were 
related. This was the first time that the spread of cancer to regional sites was described. 
Henry  LeDran  (1684-1770),  a  French  surgeon,  finally  ended  the  Galen  thesis  of  humors.  He 
stressed that cancer was a local lesion in the early stages and spread via lymphatics. LeDran observed 
that cure was much less likely when lymph nodes were involved. 
Velpeau (1856), a Frenchman, advocated bleeding, leeches, purgatives and emetics. He retained the 
Galenic ideas and used various drugs to destroy the humors. He wrote: ―To destroy a cancerous tumor 
by surgical means is usually an easy matter and but little dangerous in itself; but the question arises, 
whether such a procedure affords a chance of radically curing the patient. This proposition remains 
undecided.‖  He  further  states:  ―The  disease  always  returns  after  removal,  and  operation  only 
accelerates its growth and fatal termination.‖ (Note that this is an adumbration of Fisher‘s hypothesis 
that the disease is systemic once it presents clinically. vide infra) 
It is to be recalled that all of this was done without the availability of microscopic anatomy. Further, 
all surgery was performed without anesthesia. Nitrous oxide was described in 1842 and ether was first 
demonstrated in 1846.  Local anesthesia (cocaine) was first described in 1884. Halsted, a surgeon at 
the Johns Hopkins Medical School in Baltimore, who first described the radical mastectomy, became 
addicted to cocaine while researching the drug upon himself. 
Surgery at the time was performed without knowledge of sepsis and was often complicated by local 
and systemic infection. Louis Pasteur advocated heat to destroy bacteria, and Joseph Lister, in 1867, 
advocated carbolic acid spray to prevent infection. Not everyone accepted the theory and practice of 
preventing infection. Samuel Gross, a great surgeon of that time in Philadelphia, stated: "Little if any 
faith is placed by an enlightened or experienced surgeon on this side of the Atlantic in the so-called 
carbolic acid treatment of Professor Lister." 
Schleiden (1838), a German, was among the first to appreciate the significance of the cell as a unit 
in plant structure, and Virchow, another German, considered to be the father of pathology, advanced 
the concept that any normal cell can become a cancer cell as a result of irritation. 
Sir James Paget (1814-1899), without the availability of anesthesia or asepsis, stated: "We have to 
ask ourselves whether it is probable that the operation will add to the length or comfort of life enough 
to justify incurring the risk of its own consequences." He had an operative mortality rate of 10% in 235 
cases of breast cancer. He believed the disease to be hopeless and stated: ―In deciding for or against 
removal of the cancerous breast, in any single case, we may, I think, dismiss all hope that the operation Cancers 2010, 2                                      
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will be a final remedy for the disease. I would not say that such a thing is impossible; but it is so highly 
improbable that a hope of its occurring in any single case cannot be reasonably entertained.‖ 
This pessimistic attitude was also voiced by Robert Liston (1794-1847): "No one can now be found 
so rash or so cruel as to attempt the removal of the glands thus affected whether primary or secondary." 
Hayes Agnew (1818-1892), of the United States, resorted to surgery solely for its moral effect. He 
believed that surgery actually shortened the life of the patient. He was most pessimistic and stated: "I 
do not despair of carcinoma being cured somewhere in the future, but this blessed achievement will, I 
believe, never be wrought by the knife of the surgeon." 
 
2.6. Breast Cancer in the 19thC and Early 20thC 
 
A treatise by Dr. Gross of Philadelphia published in 1880 [7] provides a clear insight into the status 
of the disease in the  era immediately before the developments in anesthesia and antisepsis which 
allowed surgeons to attempt a radical cure of breast cancer.  He describes a series of 616 cases, 70% of 
which had skin infiltration on presentation, which had ulcerated through in 25% of the patients. 64% 
had extensive involvement of axillary nodes and 27% had obvious supra-clavicular nodal involvement. 
Accepting that the meager benefits of surgery seldom outweighed the risks in those days, he judged it 
ethical to follow the natural course of 97 cases who received nothing other than ―constitutional support‖. 
He describes how skin infiltration appeared an average 14 months after a tumor is first detected, 
ulceration appears on average six months after that, fixation to the chest wall  after a further two 
months and invasion of the other breast if the patient lived on average 32 months after the lump first 
appeared. The average time for the appearance of enlarged axillary nodes was 15 months in those few 
cases that presented with an ―empty‖ axilla to start with. 25% of all these untreated cases exhibited 
obvious  distant  metastases  within  a  year  and  25%  after  three  years  with  only  5%  surviving  more  
than 5 years.  
Since then a number of different series of untreated breast cancer have been reported. For example 
Greenwood in 1926 [8] described a 6 year follow up of 651 cases of untreated breast cancer with only 
60 remaining alive at the end of this period. Daland in 1927 [9] reported a series of 100 patients who 
were considered inoperable, unfit for surgery or who had refused the offer of surgery. The average 
duration of life was 40 months for the whole group, 43 months for those deemed operable at diagnosis 
and 29 months for those deemed inoperable. 
The study that has attracted the most attention over the years was that of Julian Bloom published in 
1968 [10]. His data came from the records of 250 women dying of breast cancer in the Middlesex 
Hospital Cancer ward between 1905 and 1933. Of this group 95% died of breast cancer but it should 
be noted that almost all of them presented with locally advanced or overt metastatic disease. The 
survival rates from the alleged onset of symptoms were 18% at 5 years, 0.8% at 15 years (remarkably, 
one person lived 16 years) with a mean survival of about two and a half years. The reasons given for 
withholding treatment are also worthy of note: old age or infirmity 35%, disease too advanced 30%, 
treatment refused 20% and early death the remainder. 
Although of historical interest we cannot really believe that these studies help to provide a baseline 
against  which  to  judge  the  curative  effect  of  modern  treatment.  Firstly,  as  with  all  retrospective 
uncontrolled series there has to be an element of selection. Why was treatment withheld? It is quite Cancers 2010, 2                                      
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obvious that in the majority of these cases, with the exception of those refusing treatment, they all had 
an  exceptionally  poor  prognosis  to  begin  with.  Secondly,  they  mostly  represent  women  seeking 
medical attention at a time in the late 19thC or early 20thC, when many women were content to coexist 
with their lump in blissful ignorance until they died of old age or were knocked down by a Hansom 
cab! Next the accuracy of the diagnosis might be called into question in the days before modern 
microscopy and the widespread adoption of the histological criteria of cancer. 
It would of course be inconceivable to suggest we study an untreated group today and the closest 
approximation we can find comes from a report of the Ontario cancer clinics between 1938 and 1956, 
just preceding the jump in breast cancer incidence in the developed world [11,12]. Close on 10,000 
cases were analyzed accounting for 40% of all new cases arising in the province of Ontario during this 
period. Amongst this group were 145 well -documented cases who received no treatment of any kind. 
Although, yet again 100 of these cases were untreated because of late stage of presentation or poor 
general condition, the rest were unable or unwilling to attend for treatment. A careful note was made of 
the date the patient first became aware of the lump from which point survival rates were computed. 
The 5 year survival from first recorded symptom was 35% with a median survival of 47 months.  
The  most  surprising  figure  was  a  near  70%  5  year  survival  for  the  small  group  presenting  with 
localized disease! 
This then raises the inevitable question, is carcinoma of the breast inevitably a fatal disease if 
neglected [12]? This question is almost impossible to answer with confidence although hinted at by 
anecdotal evidence.  
 
2.7. The Influence of Surgery on the Natural History of Breast Cancer. 
 
From the popularization of the classical radical mastectomy at the very end of the 19thC [13,14] 
until about 1975, almost all patients with breast cancer, of a technically operable stage were treated 
with modifications of the radical mastectomy. To those without commitment to a prior hypothesis, this 
allowed for new insights about the nature of the malignant process. Before considering this matter it‘s 
worth revisiting the conceptual model that allowed the radical operation to reign supreme for 75 years. 
In about 1840, Virchow described a revolutionary model of the disease building on the development 
of  microscopy  and  postmortem  examinations  of  the  cadavers  of  breast  cancer  victims  [15].  He 
suggested that the disease started as a single focus within the breast, expanding with time and then 
migrating along lymphatic channels to the lymph glands in the axilla. These glands were said to act as 
a first line of defense filtering out the cancer cells. Once these filters became saturated the glands 
themselves acted as a nidus for tertiary spread to a second and then third line of defense like the curtain 
walls around a medieval citadel. Ultimately when all defenses were exhausted the disease spread along 
tissue planes to the skeleton and vital organs. 
The  therapeutic  consequences  of  this  belief  had  to  await  the  development  of  anesthesia  and 
antisepsis in the 1880s but were seized upon by Halsted in about 1895 with his complete experience 
being described in 1932 [16]. Armed with these insights it seemed inevitable that patients would be 
cured by radical operations that cut away all of the breast, the overlying skin, the underlying muscles 
and as many lymph node groups compatible with survival. Cancers 2010, 2                                      
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So convincing were these arguments and so charismatic their chief proponent, the Halsted operation 
was adopted as default therapy all round the world. At this perspective we are entitled to ask to what 
extent did the radical operation add to the curability of the disease and what can we learn about the 
nature of the beast by its behavior following such mutilating surgery? We can also add a third question 
concerning human nature and our unwillingness to see facts ―which almost slap us in the face‖
 * [17]. 
(* ―It is now, as it was then, as it may ever be, conceptions from the past blind us to facts which almost 
slap us in the face‖ - WS Halsted 1908) 
Unfortunately, only 23% of patients treated by Halsted survived 10 years. The natural response to 
this failure was even more radical surgery. Internal mammary lymph nodes that received about 25% of 
the lymphatic drainage of the breast were not removed in the ‗complete operation‘ but included in the 
super radical operations that followed or in the fields of radiation after surgery. 
Retrospective studies indicated that more radical operations improved survival [18]. However, in 
randomized trials that followed later, no benefit could be demonstrated [19]. Thus even when the 
tumor seemed to have been completely ‗removed with its roots‘, the patients still developed distant 
metastases and succumbed: 30% of node negative and 75% of node-positive patients eventually dying 
of the disease over 10 years when they were treated by radical surgery alone [20] and with no evidence 
of ―cure‖ if patients were followed up for 25 years [21,22]. In this latter seminal study by Brinkley and 
Haybittle, a group of over 700 breast cancer patients, treated by radical surgery alone and followed up 
for 25 years, continued to demonstrate an excess mortality compared to an aged matched population. 
 
2.8. The Biological Revolution of the Late 20thC 
 
Prompted by the failures of radical operations to cure patients of breast cancer, Fisher proposed a 
revolutionary hypothesis that rejected the mechanistic models of the past [23]. He postulated that 
cancer spreads via the blood stream even before its clinical detection, with the outcome determined by 
the  biology  of  tumor–host  interactions.  Based  on  this  concept  of  ‗biological  predeterminism‘,  he 
predicted the following: 
(A) The extent of local treatment would not affect survival; and (B) systemic treatment of even 
seemingly localized tumors would be beneficial and might even offer a chance of cure. 
Several pioneers in the field set up randomized clinical trials to test these hypotheses culminating in 
a series of world overviews [24,25]. Although the ―Fisherian‖ doctrine is now taken as ‗proven‘, we 
must accept that the proof is more in principle rather than in cure. The benefits from systemic therapy 
are modest, with a relative risk reduction in breast cancer mortality of about 25%–30% overall, which 
translates  to  about  8%–10%  in  absolute  terms.  As  regards  the  extent  of  local  treatment,  many 
randomized trials have tested less versus more surgery with or without adjuvant radiotherapy. 
A recent world overview of these trials [25] concluded that more radical local treatment, surgery or 
adjuvant radiotherapy does not have any influence on the appearance of distant disease and overall 
survival with one caveat (vide infra). This is in spite of the increase in local recurrence rates with less 
radical local treatment, i.e., although radical surgery or postoperative radiotherapy had a substantial 
effect on reducing local recurrence rates, it did not improve overall or distant disease-free survival.  
The  one  exception  to  the  theory  of  predeterminism  might  be  the  ―success‖  of  the  trials  of 
mammographic screening [26]. From this it might be concluded that 25% of breast cancer deaths in Cancers 2010, 2                                      
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women aged 50–69 could be avoided if caught ―early‖ at a sub-clinical stage. Forgetting the arguments 
about the scientific reliability of these studies or the reliability of the estimate of benefit [27], at best 
this still only accounts for about 12% of incident cases i.e., failing those cases in women under 50 or 
over 70.  All the above can be taken as powerful corroboration of Fisher‘s theory that metastases of 
any importance have already occurred before the clinical or radiological detection in about 90% of all 
breast cancers. 
 
2.9. Phenomena that Challenge the Existing Models 
 
Even in the world overview there is one finding that was not completely in keeping with Fisher‘s 
doctrine of biological predeterminism. Radiotherapy does actually reduce the breast cancer-specific 
deaths  by  about  3%  -  only  to  be  counterbalanced  by  the  increased  mortality  from  late  cardiac 
complications in those patients with cancer in the left breast because of radiation damage to the heart. 
More recently, two randomized-controlled trials evaluated the benefit of postoperative radiotherapy 
after mastectomy for tumors with a poor prognosis. The radiotherapy techniques in these two studies 
minimized the dose to the heart. Not surprisingly, there was a reduction in local recurrence rates, but 
there was also an improvement in the overall 10-year survival rates—9% and 10% [28,29]. Whatever 
the  explanations  for  the  magnitude  of  effect  in  these  trials,  it  is  clear  that  more  extensive  local 
treatment is not completely ineffective in improving survival. This could mean that local recurrence is 
a source of tertiary spread, although the metastases arising from the primary tumor at the point of 
diagnosis exert most of the prognostic influence. Alternatively, and more likely, in our opinion, it 
might suggest that the additional surgery (usually a mastectomy) might trigger the outgrowth of latent 
distant metastases. (vide infra) 
 
2.10. Adjuvant Systemic Therapy Has Only a Modest Effect on Survival 
 
The development of adjuvant systemic therapeutic regimens was based on the kinetics of tumor 
growth and its response to chemotherapy in animal models [30]. However, the early clinical trials 
predicted a large benefit and were consequently underpowered to detect the modest ‗real‘ benefit. 
Consequently, there was considerable confusion, with the positive results of some of the early trials 
being  contradicted  by  negative  or  equivocal  results  of  others.  The  overview  analysis,  however, 
confirmed that adjuvant systemic therapy can in fact be beneficial [25]. It is the magnitude of benefit 
that is disappointingly modest—an absolute benefit of a maximum of 12% in high-risk premenopausal 
individuals and of 2% in equivalent-risk postmenopausal individuals is much smaller than anticipated 
from the experimental models. 
The next step taken by medical oncologists was very similar in attitude to that taken by surgeons 
only a few decades ago, if a little doesn‘t work then try a lot! This approach was bolstered by the 
excellent rate of long-term cure achieved in hematological malignancies. In addition, tumor cell lines 
showed a log–linear dose response when exposed to alkylating agents [31,32]. 
Needless to say the high dose chemotherapy with bone marrow rescue was a failure and the least 
said about this sorry episode in the history of breast cancer the better, yet there may be lessons to learn 
from the failure of this approach. Cancers 2010, 2                                      
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2.11. When Does a Primary Tumor Seed Its Secondaries? 
 
If we believe that once a primary tumor gains access to the vasculature it starts seeding metastases 
in a linear or exponential manner, it should be expected that because a larger tumor has been in the 
body for a longer time, and therefore has had access to the vasculature for longer than smaller tumors, 
a much higher percentage of patients with larger tumors should present with metastases. This is true to 
some extent with regard to lymphatic metastases, i.e., there is a correlation of number of involved 
lymph nodes with the size of the primary tumor. However, this relationship is far from linear. Thus 
there are small  or  even occult tumors that  have  several involved lymph nodes,  while  many  large 
tumors are found not to have metastasized to the axilla. This discrepancy becomes even more apparent 
when we consider distant metastases. It would be expected that the proportion of patients presenting 
with distant metastases would be higher for those with larger tumors as opposed to those with smaller 
tumors.  Nevertheless,  in  real  life  a  patient  presenting  with  a  primary  tumor  along  with  distant 
metastases is uncommon, however large the tumor. At clinical presentation overt distant metastases are 
very rare whatever the extent of local disease, yet within 2 years of surgery there is a strong correlation 
between local extent at presentation and distant relapse [33]. 
How can  this  be  explained  without challenging the linear model of breast cancer spread?  One 
explanation would be that although the number of metastases that are seeded by the primary tumor 
would be linearly related to the tumor size and biological aggressiveness, the clinical appearance of 
metastases is triggered or accelerated only after the primary tumor has been disturbed or removed. This 
conclusion  may  logically  derive  from  a  consideration  of  the  pessimistic  experiences  of  ancient 
surgeons we presented in previous sections. It also is the result of very modern day science using 
computer simulations to analyze an unexpected bimodal hazard rate of relapse for patients treated only 
with  surgical  excision  of  primary  breast  tumors  [34–36].  Hazards  are  calculated  by  dividing  the 
number of events in a particular time frame by the number of patients at risk of having those events at 
the start of the period. 
Relapse data from 1173 otherwise untreated early stage breast cancer patients with 16–20 year [35] 
follow-up display a sharp peak at 18 months, a nadir at 50 months and a broad peak at 60 months with 
a long tail extending to 15–20 years. Patients with larger tumors more frequently relapse in the first 
peak while those with smaller tumors relapse equally in both peaks. There is structure in the first peak. 
A relapse mode within 10 months of surgery is associated with premenopausal node-positive patients. 
Similar patterns to the Milan data can be identified in some but not all disease-free survival and hazard 
of relapse databases for untreated patients [37].  
Based on a computer simulation [38], breast cancer growth often includes periods of temporary 
dormancy. The second peak is the natural history of the disease. These relapses result from steady 
stochastic  transitions  from  single  cells  (dormancy  half-life  of  1  year)  progressing  to  an  avascular 
micrometastasis (dormancy half-life of 2 years) to a growing lesion that eventually becomes detected 
as a relapse. The first peak is too sharp to be the result of steady stochastic transitions. Some breaking 
of dormancy had to occur at surgery to explain the first peak.  
Accordingly,  two  previously  unreported  relapse  modes  comprise  the  first  peak.  In  the  first  
10  months,  there  are  relapses  due  to  avascular  micrometastases  (preexisting  at  primary  tumor 
detection) that are stimulated to vascularize at surgery. This surgery-induced angiogenesis mode is Cancers 2010, 2                                      
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most prominent for premenopausal node-positive patients in which case over 20% of patients relapse 
in this manner. The remainder of events in the first peak are single cells that are dormant at primary 
detection  and  are  induced  to  divide  as  a  result  of  surgery.  These  then  must  undergo  a  stochastic 
transition  to  an  eventual  growing  metastasis.  The  first  peak  comprises  50  to  80%  of  all  relapses 
depending on tumor size but independent of age.  
The top of the second peak (at 60 months) marks when the benefit of surgery is first seen. That is, 
the time that it takes a newly seeded malignant cell to become a detectable lesion is so long that the 
benefit of surgery, that stops the seeding process, does not appear as a reduction in relapses until 5 
years have passed in a patient population. This process may be thought of as a metastatic pipeline that 
is so long that it is fully 5 years after the entrance spigot is turned off before the pipeline is depleted.  
Naumov et al. [39] has observed dormant but viable single cells in a breast cancer animal model 
and  Klauber-DeMore  et  al.  [40]  has  observed  small  dormant  micrometastases  and  growing  larger 
micrometastases in human breast cancer. Folkman and colleagues [41] have reported many examples 
of dormant micrometastases in animal models. Within the dormant micrometastases there is balance 
between growth and apoptosis. There are known factors that inhibit angiogenesis and other factors that 
stimulate angiogenesis. To maintain a dormant state, inhibiting factors locally dominate. If stimulating 
factors are increased or inhibiting factors are reduced the dormant condition can cease. 
It is well documented in the Lewis-lung model that removal of the primary tumor will reduce 
angiogenesis inhibitors and it is known that after surgery a sharp spike in angiogenesis stimulators and 
growth factors occurs to aid in wound healing. Thus it is not surprising that tumor angiogenesis and 
proliferation result after surgery to remove a primary tumor. Thus a likely trigger for ‗kick-starting‘ the 
growth of micro-metastases could be the act of surgery itself.  
The first peak occurs at the same time, whether the tumor was at stage I or stage III. It is only the 
amplitude of the peak that changes with stage, the later the stage the higher is the peak, but the timing 
of the signal remains the same. 
These  phenomena  suggest  a  nonlinear  dynamic  model  for  breast  cancer,  which,  like  a  chaotic 
system, is exquisitely sensitive to events around the time of diagnosis. It might even suggest that 
surgery could be responsible for accelerating the clinical appearance of metastatic disease. However, a 
randomized trial of surgery versus no surgery to prove this would no doubt be judged unethical in the 
absence of systemic therapy. Nevertheless, such a model is fortuitously available in the setting of 
randomized trials of mammographic screening [26].  
Thus with this new perspective we come back to discussing the trials of mammographic screening. 
In these trials, surgery is delayed in the control group by about 18–24 months (lead-time) so that the 
first few years offer the comparison between no surgery in the control arm versus surgery in the 
screened  arm.  Later  years  offer  the  comparison  between  ―late‖  surgery  in  the  control  arm  versus 
―early‖ surgery in the screened arm. In a meta-analysis of screening trials for breast cancer, it was 
found that in women under the age of 50 years, there is an early excess mortality in the third year. In 
women 50 and above, there is no year with a significant excess mortality.  Since the time between 
relapse and death in breast cancer is approximately 2 years, it is reasonable to conclude that timing-
wise surgical-stimulated angiogenesis for premenopausal node-positive patients could account for the 
excess mortality in the 3rd year of trials.  Cancers 2010, 2                                      
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There is a very interesting result of extrapolating these ideas. We are saying that for premenopausal 
women in the absence of surgery, the ―natural‖ process to active angiogenesis delays metastatic growth 
by approximately 2 years. Also we know that the incidence of breast cancer for women age 30–39 is 
0.5%  and  for  women  age  40–49,  it  is  1.5%.  Thus,  due  to  this  putative  effect,  2%  of  women  of 
childbearing age live 2 years longer and could bear 2 additional children. This could result in a small 
evolutionary  pressure  in  favor  of  temporary  breast  cancer  dormancy  regulated  by  inhibition  of 
angiogenesis in premenopausal women. Colon cancer is very rare in women under age 50 but perhaps 
ovarian cancer should be examined in this perspective as well to see if an equivalent biology is present. 
Clearly a new model for breast cancer is needed that takes into account the fine dynamic balance 
between the tumor and the host, including various autocrine and paracrine factors which influence 
proliferation, apoptosis and angiogenesis. 
 
2.12. A New Model to Explain the Natural History of Breast Cancer 
 
Taking all this into account we would like to develop a new model to explain the natural history of 
the  disease  which  in  addition  to  explaining  the  success  of  the  Fisherian  model  of  ―biological 
predeterminism‖ also explains the clinical observations that fail to fit neatly into the contemporary 
early detection paradigm.  
First of all, cancer should be seen as a process, not a morphological entity [42]. Individual cancers, 
while likely to originate from single cells, are constantly adapting to the local environment. There is no 
single  substance  or  metabolic  defect  that  is  unique  to  cancer.  Clonality,  previously  considered  a 
hallmark of cancer, is neither always demonstrated in malignancy nor restricted to it [43].  
The cancer cell is largely normal, both genetically and functionally. 
The malignant properties are the result of a small number of genetic and/or environmental changes 
that have a profound effect on certain aspects of its behavior. The three main processes of cancer, 
growth, invasion and metastasis, have their equivalents in normal tissues. Most cancers are diagnosed 
by virtue of their morphological or histochemical similarity to the tissue of origin. At the genetic level, 
with the exception of deletions, all necessary information is preserved, and the defective portion of 
DNA is relatively small. The key processes of malignancy are genetically controlled by the under or 
over expression of normal genes and their products that normally serve essential cellular functions.  In 
addition, pathological and autopsy studies have suggested that most of the occult tumors in breast (and 
prostate cancers) may never reach clinical significance [44,45].  
Demicheli and colleagues [46] have also provided evidence that a continuous growth model of 
breast cancer fails to explain the clinical data. In an analysis of local recurrence following mastectomy 
for patients undergoing regular follow-up, the continuous growth model yielded tumor sizes too large 
to be missed at the preceding negative physical examinations, and required growth rates significantly 
lower than those consistent with clinical data. As mentioned before, the continuous growth model also 
fails to explain the biphasic recurrence pattern seen when hazards of recurrence are plotted for every 
year after diagnosis. 
The new model is based on the concept of tumor dormancy/latency both in the preclinical phase 
within the breast and later with the micrometastases that seed in the early phase of the natural history 
of the disease, once the primary focus has developed its microvasculature. The latter remain in a state Cancers 2010, 2                                      
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of both cellular and micrometastatic tumour dormancy until some signal, perhaps the act of surgery or 
other  adverse  life  event,  stimulates  them  into  fast  growth.  In  particular,  groups  of  cells  without 
angiogenic potential can grow but remain small (up to 10
5 or 10
6 cells). The metastatic focus may grow 
quickly if (i) a subset of these cell switches to an angiogenic phenotype and/or (ii) the inhibition of 
angiogenesis is removed. The model suggests that the metastatic development of unperturbed breast 
cancer is a sequential evolution from cellular dormancy to micrometastatic dormancy and then from a 
non angiogenic to an angiogenic state, with stochastic transitions from one state to the next.  
This model may explain the early peak of hazard function for local and distant recurrences in 
resected cancer patients by combining with the natural metastatic development of unperturbed disease 
(―the  Fisher  effect‖)  with  the  angiogenic  signal  following  surgery  (―the  Folkman  effect‖).  It  also 
correlates well with the finding of a modest benefit after adjuvant systemic chemotherapy. 
We can now add a new mathematical model to the biological model described above [36]. Breast 
cancer is like a complex organism existing in a state of dynamic equilibrium within the host, the 
equilibrium being very precarious and close to a chaotic boundary. Furthermore, the mathematics to 
describe the natural history of these ―organisms‖ invokes nonlinear dynamics or chaos theory. This 
model is the first attempt to apply the new mathematics of complexity to make predictions about the 
factors  influencing  the  natural  history  of  breast  cancer  that  might  one  day  provide  a  therapeutic 
window. 
Central  to  the  understanding  of  this  model  is  the  pioneering  work  of  Folkman  on  tumor 
angiogenesis [47]. As we know, solid tumors cannot grow beyond 10
6 cells or about 1–2 mm in 
diameter in the absence of a blood supply [48]. The initial prevascular phase of growth is followed by 
a vascular phase in which tumor-induced angiogenesis is the rate-limiting step for further growth and 
provides malignant cells direct access to the circulation [49].  
In addition to the importance of the microvasculature, we can also visualize these microscopic foci 
as existing in a ‗soup‘ of cytokines, endocrine polypeptides and steroids, with cells interacting with 
each other and with the surrounding stroma, interpreting competing signals directing the cancer cells in 
the direction of proliferation or apoptosis.   Such complexity cannot be modeled by linear dynamics, or 
even a full understanding of the complete catalogue of genetic mutations at the cellular level, because 
the critical events of multiple cell-to-cell interaction require a thorough understanding of epigenetic 
phenomena. 
What we now have is a new model of the disease that owes its genesis it part to the interpretation of 
the results of natural history data-bases or clinical trials by way of hazard rate plots rather than Kaplan 
Meyer curves. We can now see a new signal appearing against background noise that challenges the 
assumption of linear dynamics in favor of non-linear mathematics or chaos theory [36]. This ―signal‖ 
is the early peak of hazard for relapse that follows surgery within 12 to 24 months, whereas the near 
constant hazard thereafter might be the ―echo‖ of the natural history of breast cancer left unperturbed 
by surgical interference.  
If that is true then the act of wounding the patient creates a favorable environment for the sudden 
transfer of a micrometastasis from a latent to an active phase.   
The most obvious prediction of the model would be that biological events that are a natural or 
evolutionary advantage following wounding would as a side effect also favour cancer progression. (It 
should be remembered in this context that most cancers are the consequence of ageing beyond the age Cancers 2010, 2                                      
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of reproductive activity that in evolutionary terms is neutral). In fact work published in 2004 confirms 
the  similarities  in  the  gene  expression  of  fibroblasts  to  wounding  to  those  active  in  malignant  
disease [50,51]. Or as Weinberg put it ―The way that tumours acquire the ability to create complex 
tissues does not involve their de- novo invention of the complex programme of stromal activation. 
Instead they activate a latent, pre-existing wound-healing programme that is encoded in the normal 
genome, which they then use as the strategy for constructing their own stroma‖ [52]. With that in 
mind, we can note with no great surprise a slew of ―downstream‖ epi-phenomena linking molecular 
events that favour wound healing to the progression and prognosis of breast cancer. For example 
HER2  over-expression  is  closely  linked  with  the  expression  of  VEGF  [53]  both  of  which  are 
associated with a poor prognosis. The fluid from surgical drains is very potent in stimulating epithelial 
and endothelial cells and this is directly proportional to the magnitude of the operation and indirectly 
to the age of the patient [54]. COX-2 expression is associated with an aggressive phenotype of duct 
carcinoma in situ [55] and the angiogenicity of circulating malignant cells in the peripheral blood of 
breast  cancer  patients  predicts  for  early  relapse  and  resistance  to  chemotherapy  [56].  Finally  the 
paradoxical ―curative‖ effect of adjuvant Tamoxifen might be as much to do with its inhibition of the 
secretion of VEGF as to its anti-oestrogenic effect. [57].  
The therapeutic consequences of the new models are almost self evident. The intervention that 
suggests itself would be anti-angiogenic, and the timing of the intervention would be preoperative, so 
that at the time of surgery the system is primed to protect against sudden flooding with angiogenic 
signals. Indeed, some of the success attributed to adjuvant Tamoxifen or chemotherapy might be a 
result of their anti-angiogenic potential rather than cytostatic/cytocidal effects [58]. 
Assuming we can protect the subject from the first peak of metastatic outgrowth, we will then have 
to monitor her with extreme vigilance. By the time the metastases are clinically apparent it is perhaps 
too late, therefore monitoring the patient with tumor markers and reintroducing an anti-angiogenic 
strategy at the first rise in tumor markers might prove successful. 
In the meantime we can continue to add additional layers of complexity to the simulations of our 
mathematical model, to help develop alternative strategies for biological interventions to maintain the 
disease in equilibrium until nature takes its cull in old age. Unlike the hamster lymphoma models of 
the past, the new model feeds on complexity and becomes closer and closer to simulating the grand 
diversity of nature. 
 
3. Effects of Primary Surgical Removal on the Tumor System 
 
As above recalled, the surgical extirpation of primary breast cancer has been regarded with different 
attitudes trough the centuries until the twentieth century progress in antisepsis, anesthesia, and surgery 
fuelled more and more  aggressive surgical treatments. The failure of such aggressive operations to 
cure patients led to a reversion of this trend, and the last quarter century has witnessed a progressive 
reduction  of  the  extent  of  surgery,  the  biological  basis  of  which  is  embedded  in  the  hypothesis 
proposed by Fisher. 
Further, clinical investigations and mathematical modeling suggested that surgical resection might 
not always be beneficial [35,38] as, while it favorably modifies the natural history for some patients, it 
may also hasten the metastatic development for others, by triggering tumor growth. These concepts Cancers 2010, 2                                      
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seem difficult for many to accept. It is worthy, therefore, to carefully review the venerable history of 
investigations and speculations revealing the context in which these concepts were conceived and 
structured to explain experimental data. 
 
3.1. Earlier Studies: Phenomena Recognized and General Traits Outlined 
 
The capacity of tumor surgical resection to enhance cancer growth at metastatic sites was clearly 
identified almost a century ago, though the proposed mechanisms were incorrect and incomplete. In 
experiments of double inoculations of rat sarcomas a retarded growth of a subsequently injected tumor 
in comparison with the previous (―primary‖) tumor was observed [58]. A competition for essential host 
derived  nutrients  for  tumor  proliferation  (athrepsia  hypothesis)  was  hypothesized,  and  this 
phenomenon was labeled ―concomitant immunity‖, assuming that the inhibition resulted from host 
immune reaction due to the previous tumor [60]. A few years later, implanted tumors, which if allowed 
to  develop  naturally,  rarely  resulted  in  spontaneous  metastases,  were  found  to  frequently  produce 
metastases if the primary implant was incompletely excised [61]. Moreover, for a highly metastasizing 
mouse tumor, incomplete primary tumor excision resulted in larger metastases than those of the control 
mice not undergoing tumor resection [62]. Athrepsia was considered a possible reason of this observation. 
During the fourth and fifth decades of the past century, the concept of ―dormant tumor cell‖ was 
introduced to describe malignant cells which although remaining alive in the tissues for relatively long 
periods  show  no  evidence  of  multiplication  during  the  time  and  yet  retain  all  their  capacity  of  
multiplying [63]. The concept was supported by studies on the effect of partial hepatectomy, sham 
hepatectomy  and  observation  on  the  development  of  hepatic  metastases  [64–67].  Studies  with 
parabiotic pairs of animals were performed as well. In animals subjected to repeated laparotomies with 
partial hepatectomy, sham hepatectomy, liver manipulation and chemical hepatic injury, the incidence 
of metastasis progressively increased to virtually 100%. It was suggested that tumor cells remain in the 
liver in a viable but dormant state until triggered into growth by some factor or factors. By liver injury, 
cancer cells may be converted from the state of ―peaceful co-existence‖ with the host to one of active 
growth, should ―conditions‖ be appropriate. Other investigations added new details [68–75] and about 
50 years ago a few main concepts were explicitly stated [68,69]. 
  A primary tumor of sufficient size inhibits the development and growth of its distant spontaneous 
metastases.  
  Metastases become established and grow prior to the primary tumor becoming large.  
  Removal of the primary results in the establishment and rapid growth of large numbers of latent 
metastases, the majority of which would have been dormant or would have succumbed if the primary 
tumor had not been removed.  
  The growth-stimulating effects on metastases postoperatively are due to removal of primary. 
The next years marked an increasing effort to determine the details of the relationship between 
tumors in different sites, the surgery-driven effects and the tumor dormancy, which it became clear 
were intimately connected. 
The previously adopted concomitant immunity hypothesis began to show its limits when it failed to 
adequately  explain  several  findings  (e.g.  that  the  tumor  growth  at  the  s.c.  injection  site  may  be 
depressed  in  mice  that  received  artificial  metastases  in  addition  to  a  s.c.  implant,  proving  that Cancers 2010, 2                                      
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metastases can inhibit s.c. tumor growth without themselves being affected [76]). The immunologic 
hypothesis  was  finally  rejected  when  ―concomitant  immunity‖  was  demonstrated  in  immune-
suppressed animals [77,78] and it was concluded that resistance of mice bearing immunogenic and 
non-immunogenic  tumors  is  mediated  by different mechanisms.  The  resistance  to a  second tumor 
challenge in mice bearing non-immunogenic tumor is due mainly to non-immunological mechanisms. 
The term ―concomitant immunity‖ was appropriately changed to ―concomitant resistance‖.  
At the end of this phase of cumulative investigations, it was recognized [79] that a number of 
observations supported the idea that a tumor is an integrated, organ-like entity rather than a collection 
of independent atypical cells.  In  particular, it was pointed out  that  the  only  significant difference 
between organ growth, organ re-growth after partial resection, and tumor growth is the resetting of the 
plateau  size  upward  in  tumors.  Concomitant  resistance  is  an  asymmetrical  non  immunologic 
phenomenon,  where  the  inhibited  tumor  is  always  the  smaller  tumor  and  the  larger  tumor, 
paradoxically, continues to grow.  
This series of phenomenological studies was concluded by investigating in animal models both 
tumor cell population kinetics and host survival time [80]. It was found that early surgical excision of 
the primary s.c. tumor provided some long term ―cures‖ and an increase in lifespan over the untreated 
controls. Later excision was, however, non-curative and resulted in an increase in the proliferation and 
growth  rate  of  metastases.  This  surgery  induced  stimulation  of  the  metastatic  nodules  was 
accompanied  by  a  small  but  consistent  decrease  in  median  lifespan.  Artificial  metastases  were 
inhibited by the presence of a second subcutaneous implant and the median lifespan of the doubly 
implanted mice exceeded that of mice bearing intravenous implants only. It was concluded that in mice 
bearing  widely  metastasized  carcinoma,  surgery  alone  may  have  a  detrimental  effect  on  life 
expectancy.  
 
3.2. More Recent Times: Looking for the Mechanisms 
 
As the era of breast cancer  conservation  surgery emerged,  the mechanisms  of local recurrence 
following primary tumor removal were center-staged and the effect of surgical trauma was actively 
investigated.   
A few early reports on growth parameters of double tumor implants [81–83] proved that following 
removal of one of the tumors, changes occur within 24 hr in the proliferation kinetics of the residual 
focus. There was a transient increase in tumor growth rate and a measurable increase in the size of the 
remaining tumor and there was also evidence for the presence of a serum growth factor that might be 
responsible for the phenomenon. The findings thoroughly refute the idea that removal of a primary 
tumor is a local phenomenon with no other biological consequences.  
It was also proven that surgical trauma of normal tissue promotes implantation and/or growth of 
circulating cancer cells [84–88] and that extent of trauma influences the metastatic success rate of 
these circulating tumor cells [84]. It was confirmed that the ability of malignant tissue to respond to 
surgical wounding of normal tissue is not tumor cell type or even species specific and that the effect is 
temporary,  diminishing  as  the  wounds  heal  [85–87].  Neo-angiogenesis  elicited  by  mechanisms  of 
wound healing is apparently crucial to tumor growth [87] and wound fluids are both directly mitogenic 
to tumor cells [88] and angiogenic to avascular microscopic tumors [87]. Among the many mediators Cancers 2010, 2                                      
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in  wound  healing,  transforming  growth  factor  beta  (TGF-beta)  and  basic  fibroblast  growth  factor 
(bFGF) proved to prominently increase tumor growth at an extent nearly similar to wound fluid [89]. 
Basic aspects of the relationship between primary tumor and its metastases were made even clearer 
by the experimental studies of Folkman [41,90,91], including evaluation of DNA synthesis, apoptosis, 
corneal micropocket assay for angiogenesis and newer technologies apt to purify biological molecules. 
While in mice with an intact primary tumor, metastases appear as microscopic perivascular cuffs or 
thin colonies of tumor cells on pleural surfaces, after removal of the primary tumor, large highly 
neovascularized growing metastases may be observed. DNA synthesis is similar in both situations; 
apoptosis is however significantly diminished in the growing metastases. In a particular experimental 
setting, when the primary tumor is present, metastatic growth is suppressed by circulating angiogenesis 
inhibitors (Angiostatin and Endostatin). It may be assumed that primary tumors secrete inducers of 
angiogenesis and also generate inhibitors of angiogenesis and that when inducers and inhibitors are 
shed into the circulation, levels of the more labile inducers fall off rapidly whereas levels of the more 
stable inhibitors create a systemic antiangiogenic environment that prevents small nests of metastatic 
cells from inducing neovascularization. As a result, these incipient tumors remain small and dormant. 
Upon removal of the primary tumor, inhibitor levels fall and the previously dormant metastases expand 
vigorously. The central role of this angiogenesis switch in explaining some features of the metastatic 
process has been extensively confirmed [91–96]. 
The  previously  hypothesized  single  cell  dormancy  condition  has  also  been  identified  and  
studied [97,98]. Elegant quantitative investigations by several sophisticated techniques including in 
vivo videomicroscopy proved that a large proportion of injected tumor cells persist as solitary dormant 
cells. These cells can be recovered as viable cells long after they have been administered. It has been 
further demonstrated, by direct inspection, that single tumor cells reside in metastasis free organs of 
mice  harboring  growing  metastases  in  other  organs,  and,  furthermore,  that  they  resume  the  same 
proliferative  and  metastatic  capability  as  their  ancestors  after  rescue  and  reseeding  [98].  The 
mechanism underlying the single cell dormancy condition is  an object of active investigation and 
findings support the concept that the fate of disseminated tumor cells is fundamentally determined by 
tissue microenvironmental signals. In particular, a number of data suggest that Extracellular Signal-
Regulated Kinase (ERK) and p38 pathways may be involved [99]: high ERK/p38 signaling ratio is 
apparently correlated to proliferation whereas the opposite occurs in cellular dormancy.  
 
3.3. Findings from Clinical Studies 
 
Findings of the early experiments in rats [59] were paralleled in clinical investigations on host 
resistance factors where, in autotransplantation tests of cancer cells (in incurable patients), it was found 
that  even  when  1  million  cells  in  suspension  are  injected  subcutaneously  less  than  50%  of  the 
transplants ―take‖ [100]. Also,  it was observed [101], although  on a small  series  of  patients, that 
surgical removal of bulky metastases of non-seminomatous germ-cell testicular cancer was followed 
by a sudden and dramatic exacerbation of the disease, thus suggesting that cytoreductive surgery in 
patients with advanced testicular tumor in some cases may adversely alter the course of the malignancy.  
Even more direct evidence of surgery induced changes of metastasis steady state was achieved in a 
study of the vascular density in patients with hepatic metastases from colorectal carcinoma undergoing Cancers 2010, 2                                      
 
 
324 
biopsies or resection for synchronous metastases or resection for metacronous metastases [102]. It was 
found that both peritumoral and intratumoral vascular density were elevated in synchronous metastases 
from patients with the primary tumor removed compared to synchronous metastases from patients with 
the primary tumor in situ. More importantly, an increase in vascular density after resection of the 
colorectal malignancy was observed in biopsies taken from the same patient.  
The study of biological fluids in patients undergoing surgical procedures has also been revealing. 
Vascular endothelial growth factor (VEGF) increases postoperatively in sera of patients undergoing 
surgery for lung [103] and gastric [104] cancer. For breast cancer, wound drainage fluid was found to 
include  EGF-like  growth  factors  [105],  VEGF  [106,107],  endostatin  [107]  and  other  unidentified 
proliferation inducers [105] at levels significantly higher than the corresponding serum levels. The 
concentration of these substances correlate with the amount of surgical damage associated with tumor 
resection [105]. In particular, wound drainage fluid and postsurgical serum samples stimulated in-vitro 
growth of HER2-overexpressing breast carcinoma cells [105].  
Finally, strong direct support for tumor dormancy in breast cancer was recently provided in an 
investigation on the incidence of circulating tumor cells (CTC) in disease free patients several years 
following mastectomy [108]. Fifty nine percent of women displayed CTCs. As, after primary tumor 
removal, CTC half-life is a few hours, it should be concluded that several years after primary tumor 
removal, clinically silent tumors foci may exist and continuously shed CTCs.  
 
3.4. A New Way to Address the Question 
 
In spite of experimental evidence, the idea that surgical cancer resection has both beneficial and 
adverse effects upon cancer spread and growth that result from the modulation of tumor dormancy by 
the resection has continued to cause denial and consternation among clinicians. In all probability, it 
occurs because of a reductionist perception of cancer as resulting from invading alien enemies that 
need  be  completely  destroyed  in  order  to  achieve  the  cure.  In  this  framework  it  is  difficult  to 
understand that the primary tumor may exert influences upon distant metastases resulting in inhibited 
proliferation and/or enhanced apoptosis, mimicking the organ homeostasis that maintains the ultimate 
organ mass following the growth process. A new conceptual approach to cell and tissue functioning 
has been recently proposed, however, within which tumor homeostasis may be better understood [109].  
In  the  classical  approach  to  molecular  biology,  cell  functioning  results  from  the  activation  of 
regulatory pathways, which represent a linear chain of causal relationships explaining a particular 
phenotype. Yet, this conceptual framework is challenged by the findings that there is significant cross 
talk between pathways at almost every level of the signaling cascade, that the same molecule may 
control the expression of up to hundred genes and, conversely, a single gene may be controlled by 
several regulatory proteins. The advent of genomics and proteomics technologies has further emphasized 
the idea that molecular pathways are just parts of a complex genetic regulatory network (GRN). 
Genes regulate each other and, in addition, epigenetic regulations are present. Thus, genes cannot 
change  their  activity  independently  because  of  interactions  introducing  constraints  to  the  network 
organization, with the consequence that only given gene profiles (cell phenotypes) are permitted (are 
stable).  In  tissues,  cell  functionality  is  conserved  under  random  perturbations  from  the 
microenvironment and additionally the cell is able to undergo specific adaptive changes. Phenotype Cancers 2010, 2                                      
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stability  may  be  explained  by  the  fact  that  the  GRN  displays  a  number  of  stable  ―attracting‖ 
configurations, with a neighboring ―basin of attraction‖, corresponding to all states from which the 
system  comes  back  to  the  ―attractor‖.  However,  under  certain  perturbation  spurs,  the  GRN  may 
undergo an avalanche of significant changes in gene expressions and, following a transient phase, it 
may  reach  a  new  ―attractor‖  (stable  profile),  thus  showing  an  adaptation  process.  It  should  be 
emphasized that attractors are self-stabilizing discrete states determined by the mutual interactions of 
the network components. The provocative idea that the genome is a self-stabilizing entity has been 
recently  supported  by  an  analysis  of  the  entropy  changes  during  differentiation  of  hematopoietic 
progenitors to derived erythroid and neutrophil cell types [110].  
The concept that stable states may emerge from interacting elements may also be used at the tissue 
level,  i.e.,  when  interacting  elements  are  cells  [109].  Interactions,  embodied  by  molecular  or 
mechanical cell-cell communications, would accordingly generate tissue level attractors, ultimately 
sustaining tissue and organ homeostasis. Examples of this picture come from normal organs, such as 
the liver,  where  changes  in  some  significant  parameter  may  result  in  large  organ  rearrangements. 
Experimental  evidence  has  also  been  provided  in  studies  performed  in  3-dimensional  cell  culture 
systems consisting of collagen-I gel, where myoepithelial cells derived from normal mammary gland of 
mice are co-cultured with luminal epithelial cells and ―spontaneously‖ organize into acini-like structures. 
Looking at cancer from the GRN dynamics approach, we may conceive that a rewiring of the 
network  architecture  by  genetic  or  epigenetic  changes  may  reshape  the  attractor  landscape,  hence 
allowing  the  cell  to  acquire  new,  self-stabilizing  gene  expression  programs  still  preserving  basic 
cellular functions. In particular, the characteristic traits of tumor phenotype (proliferation, migration, 
invasion, angiogenesis, etc.) would not be de novo inventions, but co-opted from early self-organizing 
attractors, inaccessible in the normal mature tissue and made re-accessible because of altered attractor 
landscape. In other words, the new approach basically suggests that most of the tumor hallmarks could 
be considered normal-like yet de-contextualized processes, due to altered network architecture. This 
concept is supported by experimental findings indicating that normal cells may display cancer-like 
behavior and, conversely, cancer cells may regain normal cell traits [111–115]. In particular, neoplastic 
tissue would not entirely escape general behaviors and would at least in part comply with tissue level 
attractors.  Accordingly,  a  main  perturbation  like  primary  tumor  surgical  removal  may  induce  a 
rewiring  if  the  tissue  network  architecture  implying  dormant  metastasis  switch  to  a  growing  
phase  [116].  The  pattern  of  clinical  recurrence  may  be  then  considered  an  indicator  of  this 
phenomenon, which generates a time frame for the clinical development of the disease.  
 
4. A New Point of View for a Few Uncertain Questions 
 
4.1. Mammography Paradox for Women Age 40–49  
 
With the reasonable probability that screening would detect more and more cancers in very early 
states, it was expected that mammography screening would result in a major reduction in breast cancer 
mortality. Trials testing this hypothesis were begun in the 1960s and still continue. To avoid a bias, 
―intent to treat‖ analyses are done based on invitation to screening rather than those who are actually 
screened. Individual trials to determine the value of mammography for young women were producing Cancers 2010, 2                                      
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confusing results, so all such data were presented and reviewed at a NIH Consensus Conference in 
1997 and in follow-up papers [117,119]. Restricting our discussion to the 7 large trials conducted 
before  the  widespread  use  of  adjuvant  chemotherapy,  for  women  age  50–59  there  was  an  early 
appearing 20–30% mortality reduction resultant from the early detection of breast cancer. However, 
among women age 40–49, there was an early mortality disadvantage during the first 6–8 years after 
screening started. Afterwards, some advantage appeared in trials and overviews.  
Because of these unexpected and unwelcome results, the trials particularly for young women have 
been  carefully  scrutinized and rescrutinized and it was easy to criticize the trials and  dismiss the 
unsettling data demonstrating harm from mammography in some young women. But these data are all 
we have. If we discard them, we are left to make decisions based on our personal biases [120,121]. 
We observed that screening and control arms, even if similar due to randomization, have different 
surgery timing distributions within the natural history of breast cancer development, resulting from the 
early recruitment of breast cancer diagnoses for the screening arm only. We calculated that surgery-
induced angiogenesis as determined by the Milan data would cause 1 early death per 10,000 screened 
young women in the 2nd or 3rd year after starting screening [120].  The effect accelerates mortality by 
2 years since that is the undisturbed half-life of the pre-angiogenic dormant state. This effect would be 
most apparent in the early years of each trial. Both magnitude and timing agree with the individual 
trials and overviews of the 7 relevant trials conducted over decades of time and in different countries.  
 
4.2. Highest Sensitivity to Adjuvant Chemotherapy for Premenopausal Node-positive Patients 
 
Following early trials, clinical consensus reports from the years shortly after the introduction of 
adjuvant  chemotherapy  for  breast  cancer  (1980  and  1985  National  Institutes  of  Health  Consensus 
Development  Conferences)  recommended  using  adjuvant  chemotherapy  for  premenopausal  node-
positive patients. Only in later years, after careful analysis of much larger trials with longer follow-up, 
was it determined that adjuvant chemotherapy is of some value in subsets of node-negative disease, or 
in  any  patient  with  positive  nodes.  The  additional  curative  benefit  of  adjuvant  chemotherapy  is 
approximately 12% for premenopausal node positive patients and in the 2%–6% range for all other 
categories [122].  
These  findings  are  consistent  with  our  metastasis  model  that  includes  sudden  release  from 
dormancy  in  synchrony  to  surgery.  The  rapid  growth  of  micrometastases  and  corresponding  high 
chemosensitivity occurs just at the time when adjuvant chemotherapy was empirically determined to 
be most effective [123,124]. However, an avascular micrometastasis and a single tumour cell will 
reach the clinical level in different times.  A detailed study of the recurrence dynamics following 
adjuvant chemotherapy with CMF, indeed, demonstrated that the CMF recurrence
 rate reduction is 
largely restricted to two specific temporally
 separate recurrence clusters occurring during the first and 
third year of follow-up, while
 the second-year recurrences are weakly affected [125]. The dynamics of 
both  post  treatment  recurrence  risk  and  CMF  effectiveness
  are  similar  for  both  pre-  and  post-
menopausal women, albeit of considerably higher magnitude in pre- than in post-menopausal women. 
Therefore, the model provides numerically consistent reasons why adjuvant CMF given following 
surgical resection of the primary cancer is more effective for premenopausal patients than it is for 
postmenopausal patients.  Cancers 2010, 2                                      
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4.3. Heterogeneity of Breast Cancer and Aggressiveness of Breast Cancer in Young Women 
 
Breast  cancer  is  well  known  as  a  disease  exhibiting  substantial  heterogeneity  and  extreme 
variability in outcome for patients within single prognostic categories. Our model suggests that the 
disease course following primary tumor surgical removal basically follows a common pathway with 
well defined steps (dormant states) and that the pace (time to transition between states) of the common 
pathway is governed by pre-existing tumor and host traits (risk factors) [116]. The concept that for a 
given patient a unique mix of tumor and host factors and initial conditions may control the ability of 
tumor cells to progress through successive dormant states eventually resulting in clinical recurrence 
may  be  considered a reasonable explanation for  some  of this  heterogeneity. Therefore, the model 
provides a frame for a more quantitative detailing of the disease course, i.e., for a measure of its 
"aggressiveness".  For  example,  breast  cancer  in  young  women  is  often  labeled  ―aggressive‖  by 
clinicians.  This refers to the high proportion of relapses that appear very shortly after diagnosis of 
primary  disease  and  ensuing  surgery.    From  our  perspective,  this  term  well  fits  the  20%  of 
premenopausal node-positive patients that relapse within one year of surgery as a result of surgery-
induced angiogenesis. 
 
4.4. Excess Breast Cancer Mortality for African American Women 
 
There  is  an  excess  mortality  in  breast  cancer for  African-American  (AA)  women  compared  to 
European-American (EA) women that first appeared in 1970s and has been worsening since [126–131]. 
The differential access to medical care and screening and even disparities in disease management 
(diagnostic procedures, treatment decisions, etc.) are sometimes considered the source of the different 
race-related outcome. Socioeconomic explanations are indubitably very important, but they are not 
sufficient because there is a crossover in excess mortality at age 57. That is, AA patients diagnosed 
under age 57 have higher breast cancer mortality than EA but over age 57, AA have less breast cancer 
mortality than EA.  
It is known that the average age of diagnosis of African-American women is 46 while it is 57 for 
European-American women. In the above section on the ―mammography paradox‖ we explained the 
biological reasons why mammography is more beneficial for postmenopausal women than it is for 
premenopausal women. Therefore, it should be expected that after the introduction of mammography 
in the 1970s, there will be mortality advantages to EA over AA. In other words, the mammography 
screening  introduction  may  be  considered  as  a  probe  revealing  different  traits  in  the  host-disease 
balance in AA and EA, which are reflected by the change in mortality dynamics. Therefore, while it is 
obviously  essential  to  equalize  access  to  healthcare,  solving  ethnic  disparities  may  still  require 
understanding and effectively addressing other biology-based racial differences [132]. 
 
5. Concluding Statements 
 
We have shown indirect but compelling evidence that there is dormancy in breast cancer and that 
surgery  to  remove  the  primary  tumor  does  occasionally  break  dormancy.  The  ability  to  provide 
explanations for such a wide variety of effects in breast cancer with a single hypothesis to us is a Cancers 2010, 2                                      
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strong hallmark of a valid theory. That is, it is no surprise that the computer simulation agreed with 
Milan data since it was built to do that. But then, what else does it tell us that we did not know 
beforehand? 
Figure 1 is reminiscent of the parable of the seven wise blind men from Hindustan who are each 
trying to describe an elephant. One feels the tail and notes that an elephant is a rope. Another feels the 
leg and says an elephant is a tree trunk, etc. From our perspective, the mammography specialist who 
sees  paradoxical  results  from  early  detection  of  breast  cancer  among  young  women  who  then 
proclaims the trials must have been erroneous, the surgeon who notes that breast cancer in young 
women is an aggressive disease, and the medical oncologist who knows premenopausal node positive 
patients respond best to adjuvant chemotherapy are blind to the biology of tumor dormancy and its 
reawakening by surgical intervention. 
 
Figure 1. We have suggested that surgery kick-starts growth of dormant micrometastases. 
This  effect  increases  with  primary  tumor  size  and  in  particular  surgery  induces 
angiogenesis in 20% of premenopausal node-positive patients. This one hypothesis seems 
to explain a variety of previously unconnected effects in breast cancer.  
Surgery driven escape from 
dormancy  increasing with 
tumor size. Earliest events 
for young  N+ patients
Mammography paradox for 
women age 40-49
High sensitivity to adjuvant 
chemotherapy only for 
premenopausal N+ patients.
Effectiveness of Single course  
neoadjuvant chemotherapy 
Heterogeneity of breast cancer 
and ‘aggressiveness’ of breast 
cancer in young women
Popular myths:
- ‘cancer spreads when the air hits 
it’. African Americans 
- Surgery ‘provokes’ cancer. Africa.
Breast cancer in Africa: a common problem is 
that women often present with locally advanced 
disease.
Excess breast cancer 
mortality of US blacks  
Clinical recommendations from 
pre-modern surgeons:  remove 
only early stage tumors. 
Otherwise surgery would 
accelerate death. 
Bimodal relapse and mortality patterns in US, 
Europe and Asia breast cancer databases. Metastatic disease at presentation is uncommon but within 2 
years, relapses are frequent increasing with tumor size and 
number of positive nodes.
 
 
Another test if a theory is valid is whether non-obvious predictions based on the theory are correct. 
The predictions from Demicheli et al. Cancer 2007 [126] and the proposed therapy from Retsky et al. 
BMC Cancer 2009 [133] can be considered key testable predictions. Surgery-induced angiogenesis 
that is mainly restricted to node positive patients who are premenopausal would be the most noticeable 
in clinical situations since the patient category is small, distinct, and the relapses occur so soon after 
surgery.  Longitudinal  or  serial  imaging  coupled  with  angiogenic  biomarker  studies  started  before 
surgery for young patients who may be node positive would be very useful. Recent detailed analysis of Cancers 2010, 2                                      
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clinical  data  for  individual  patients  by  Hanin  and  Korosteleva  indicating  metastases  growth 
acceleration after surgery shows relevant measurements can be extracted from clinical situations [133].  
We have not proven that the dormant states involved are restricted only to nondividing single cells 
or  avascular  micrometastases.  Dormancy  of  these  two  states  and  its  breaking  after  surgery  are 
numerically consistent with the Milan data but truth be told, we have not fully examined if other 
micrometastatic size dormant states might also provide adequate fit to the Milan data. There could be 
various  biological  mechanisms  preventing  tumor  growth  and  terminated  by  some  connection  to 
surgery [57]. Thus the title of this paper is intentionally left vague as to which of the various possible 
dormant states are perturbed by interventions. As an overall statement, the positive predictive power of 
our model is impressive and we suggest it should be considered as the leading candidate for the model 
that best describes how breast cancer progresses. 
We have not shown how this model can be combined with cancer stem cell theories. That would be 
an important development. Cancer stem cells are associated with dormancy so there may a connection 
as yet unidentified. We have also not shown whether this theory has any relation to Her-2 as a marker 
for early relapse and benefit from Herceptin. With recent availability of gene chips, there has been 
much activity with correlating breast cancer relapse or mortality with genetic profiles among patient 
populations. We would advise that these correlations should be segmented according to the different 
disease progression patterns that we have identified. That is, just looking for gene assay correlations 
with survival ignores the multiple biologic pathways that breast cancer can take. We suggest research 
in this field be along the lines as reported by Zhang et al. [135]. 
Other cancers also need to be carefully examined. There are data showing indications of similar 
activity  especially  in  melanoma  [136]  and  osteosarcoma  [137].  The  information  provided  in  this 
document will help scientists identify dormancy and surgery induced growth in other cancer sites. The 
ultimate value of this knowledge is to propose new methods of intervention that may reduce mortality 
and morbidity. We suggest some progress has been made in this regard in breast.  
We have covered much terrain and history in breast cancer. There have been many persons in the 
5000 years of breast cancer intervention who have made important contributions but we wish to draw 
particular attention to Bernard Fisher and the late Judah Folkman.  
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